Clinical Trial Update: GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia [Phase 1]

View source ↗

Summary

Completed Phase 1 trial of GTI-2040 in adults with relapsed or high-risk acute leukemias, myelodysplastic syndromes, or refractory/blastic phase chronic myeloge…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelogenous Leukemia Blast Crisis
• Untreated Acute Lymphoblastic Leukemia
• Untreated Acute Myeloid Leukemia

Drugs mentioned

• GTI-2040 (GTI-2040)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 1 | Status: COMPLETED